DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the market capitalisation of CCME Global Ltd?

CCME Global Ltd has a market capitalisation of approximately ₹520 crore.

CCME Global Ltd

GENESISIBRCINDIALTD·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Biotechnology

A steady, established business

52W₹23

₹185-14%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹520 Cr

P/E Ratio

N/A

P/B Ratio

12.98

EPS

₹2.69

Book Value

₹8.86

ROE

-2.92%Weak

ROCE

51.62%Efficient

Dividend Yield

0.00%

Debt / Equity

0.00Low

Face Value

₹10.00

52W High

₹184.90

52W Low

₹23.39

Sector

Healthcare

Industry

Biotechnology

Fairly Valued

None moatHigh uncertainty

Fair value estimate

₹8

No recent traded price

BearFair valueBull

₹7₹8₹9

/100

Business quality — Solid

Growth 50Profitability 0Efficiency 100Valuation 100

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet
Weak returns on equity (-3%)

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 52%)
Promoters hold a controlling stake

Risks

Weak returns on equity (-3%)

How we got there

Fair value methods

Residual income

-0% ROE fading to 12% over ~3 yrs, on ₹9 book

₹8

Relative P/E

Needs positive EPS

—

Graham floor

Needs positive EPS

—

Analyst target

No analyst coverage

—

Blended fair value₹8

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Capital is working hard (ROCE 52%)
Promoters hold a controlling stake

Bear case

Weak returns on equity (-3%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

—

ROE

-2.9%Weak

Above 15% is considered healthy for Indian equities

ROCE

51.6%Efficient

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹520 Cr

P/B

12.98

EPS

₹2.69

Div Yield

—

What changed

Recent changes

Promoters+0.18% stake last quarter

What matters

News impact

Overview

Valuation

N/A

No P/E

Growth

N/A

No history

Profitability

Loss-making

-2.9% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

No growth history

Not enough annual history to compute CAGR.

Profile

Pros

Company is almost debt free.
Promoter holding has increased by 62.8% over last quarter.

Watch-outs

Cons

Stock is trading at 13.0 times its book value
Company has low interest coverage ratio.
Company has a low return on equity of -2.66% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Apr 2026

Promoters raised their stake by 0.18 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

74%

Promoter

Promoters

74.3%+0.18

Public

9.2%-15.88

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

16.5%

Total shareholders

1,947+9 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter74.35%

Public9.19%

Others16.46%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1992, Genesis IBRC India Ltd (Formerly SSK Lifestyles Limited) is in the business of Biotechnology.

CCME Global Ltd valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

CCME Global Ltd peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD CIPLA LTD LUPIN LIMITED MAX HEALTHCARE INS LTD MANKIND PHARMA LIMITED DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD LAURUS LABS LIMITED

Compare CCME Global Ltd with peers

CCME Global Ltd vs SUN PHARMACEUTICAL IND L CCME Global Ltd vs DIVI S LABORATORIES LTD CCME Global Ltd vs TORRENT PHARMACEUTICALS L CCME Global Ltd vs APOLLO HOSPITALS ENTER. L CCME Global Ltd vs ZYDUS LIFESCIENCES LTD CCME Global Ltd vs CIPLA LTD

CCME Global Ltd

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

CCME Global Ltd valuation & research

CCME Global Ltd peers in Healthcare

Compare CCME Global Ltd with peers

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Ownership breakdown

Ownership over time

Frequently asked questions